As the activation of c-Met promotes a protection against sorafenib-induced cytotoxicity, we next checked whether c-Met can modulate sorafenib-induced ROS generation in renal cell carcinoma (RCC) cells. This evidence concerns the gene MET and hereditary clear cell renal cell carcinoma.